Nanoparticle Immunotherapy Reducing Cancer Recurrence Extending Survival Rates with Dr. Frank Bedu-Addo PDS Biotechnology TRANSCRIPT
Release Date: 08/25/2025
Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx TRANSCRIPT
Empowered Patient Podcast
Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform. Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues. Michael explains, "So OptimizeRx is a health...
info_outline
Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx
Empowered Patient Podcast
Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform. Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues. Michael explains, "So OptimizeRx is a health...
info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outlineDr. Frank Bedu-Addo, President and CEO of PDS Biotechnology, focuses on the challenge of cancer recurrence and the development of a targeted immunotherapy approach using nanoparticle technology. Their lead immunotherapy candidate is designed to train the immune system to detect and attack microscopic or undetectable cancer cells, prolonging survival by preventing recurrence. Early clinical results in cervical, head and neck, and other HPV 16-positive cancers have been promising, showing sustained immune response leading to long-lasting T cell memory.
Frank explains, "Recurrence of cancer after treatment is actually one of the bigger hurdles we face in successfully treating cancer. So, PDS Biotechnology, as you know, we have a sharp focus on advancing our targeted immunotherapy platforms to address significant unmet needs in treating cancer. And this is actually one of those key unmet needs in cancer today. The prevailing hypothesis on knowledge is that cancer treatment, whether it's done using radiation therapy or anti-cancer drugs such as chemotherapy, both methods actually work by destroying cancer cells or halting the growth."
"And so what may happen with time is that these remaining cancer cells may then grow until they can be detected or begin to cause symptoms. Now, even if the cancer has been removed by surgery, there is still a risk that some tiny microscopic cancer cells could still remain in the body. We would therefore expect the ideal immunotherapy to be able to detect these tiny microscopic cancer cells, even if they have spread to other parts of the body."
#PDSBiotech #Cancer #CancerVaccines #ImmunoOncology #CancerRecurrence
